Showing 5031-5040 of 7311 results for "".
- Allergan Aesthetics Rolls Out Juvéderm Volux XChttps://practicaldermatology.com/news/allergan-aesthetics-rolls-out-juvederm-volux-xc/2461507/Allergan Aesthetics' Juvéderm Volux XC is now available at aesthetic practices nationwide. The filler is approved for patients older than 21 with moderate to severe loss of jawline definition. "With 40% of aesthetically-aware consumers considering tre
- ASA Earns Candid's Platinum Seal of Transparencyhttps://practicaldermatology.com/news/asa-earns-candids-platinum-seal-of-transparency/2461505/The American Skin Association (ASA) recieved Candid's Platinum Seal of Transparency, previously recognized as GuideStar's Platinum Seal of Transparency. Candid collects nonprofit data, and this designation demonstrates that ASA is an organization focused on measuring progr
- Dr. B Expands Telehealth Service into Dermatologyhttps://practicaldermatology.com/news/dr-b-expands-telehealth-service-into-dermatology/2461498/Telehealth service Dr. B added several specialties to it service network, including dermatology. The move allows patients to access low or no-cost virtual doctor consultations for a variety of conditions from home. Dr. B’s online consultation fee is $15 for paying p
- Enrollment Complete for Journey’s Phase 3 Trials of DFD-29 in Papulopustular Rosaceahttps://practicaldermatology.com/news/enrollment-complete-for-journeys-in-phase-3-trials-of-dfd-29-in-papulopustular-rosacea/2461492/Journey Medical Corporation’s Phase 3 clinical trial program of DFD-29 for papulopustular rosacea is now fully enrolled. The Phase 3 clinical trials are part of a collaboration with Dr. Reddy’s Laboratories Ltd. for the ongoing development and commercialization of the D
- Can Harnessing a Tumor’s Power Help Heal Diabetic Foot Ulcers?https://practicaldermatology.com/news/can-harnessing-a-tumors-power-help-heal-diabetic-foot-ulcers/2461480/Scientists may have found a way to train healthy immune cells to accelerate diabetic wound healing. The findings appear in EMBO Molecular Medicine. Diabetic foot ulcers result in
- UCSF Apologizes for Dermatology Experiments in Prisoners in 1960shttps://practicaldermatology.com/news/ucsf-apologizes-for-dermatology-experiments-in-prisoners-in-1960s/2461477/The University of California, San Francisco apologized for conducting unethical dermatology experiments on at least 2,600 incarcerated men in the 1960s and 1970s. Experiments included putting pesticides and herbicides on the men’s skin and injecting it into the
- Leo Pharma's Adtralza Gets Nod or Adults with AD in Japanhttps://practicaldermatology.com/news/leo-pharmas-adtralza-gets-nod-or-adults-with-ad-in-japan/2461476/The Japan Ministry of Health, Labor and Welfare has granted approval for the manufacturing and marketing of LEO Pharma’s Adtralza (tralokinumab) subcutaneous injection for adults with atopic dermatitis, which has inadequately responded to conventional therapies. “Today&
- First Participant Randomized in Dermaliq Therapeutic's Phase 1b/2 Trial Evaluating DLQ01 for AAhttps://practicaldermatology.com/news/first-participant-randomized-in-dermaliq-therapeutics-phase-1b2-trial-evaluating-dlq01-for-aa/2461470/The first participant has been randomized in a Phase 1b/2a trial of Dermaliq Therapeutics Inc.’s DLQ01 solution in men with androgenic alopecia. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ01 in men with and
- Sirnaomics' STP705 Shows Promise in Adults with Cutaneous Squamous Cell Carcinoma In Situhttps://practicaldermatology.com/news/sirnaomics-stp705-shows-promise-in-adults-with-cutaneous-squamous-cell-carcinoma-in-situ/2461469/Sirnaomics' STP705 shows promise for the treatment of Cutaneous Squamous Cell Carcinoma In Situ (isSCC), according to interim results of part-one of an ongoing Phase IIb clinical trial. The majority (78%) of 32 patients with STP705 treatment achieved histologica
- Promising and Consistent Topline Results Seen in Phase 3 Trial of Roflumilast in ADhttps://practicaldermatology.com/news/promising-and-consistent-topline-results-seen-in-phase-3-trial-of-roflumilast-in-ad/2461466/Arcutis Biotherapeutics, Inc.’s roflumilast met the key primary and secondary endpoints in the INT